The Walter and Eliza Hall Institute of Medical Research is Australia's oldest medical research institute. In 2011, the institute is home to more than 650 researchers who are working to understand, prevent and treat diseases including blood, breast and ovarian cancers; inflammatory diseases (autoimmunity) such as rheumatoid arthritis, type 1 diabetes and coeliac disease; and infectious diseases such as malaria, HIV and hepatitis B and C. Located in Parkville, Melbourne, it is closely associated with The University of Melbourne and The Royal Melbourne Hospital. The institute also has a campus at La Trobe University. The institute was founded in 1915 using funds from a trust established by Eliza Hall following the death of her husband Walter Russell Hall. The institute owes its origin to the inspiration of Harry Brookes Allen, who encouraged the use of a small portion of the charitable trust to found a medical research institute. The vision was for an institute that 'will be the birthplace of discoveries rendering signal service to mankind in the prevention and removal of disease and the mitigation of suffering.’
The first three-dimensional image capturing a critical malaria 'conductor' protein could lead to the development of a new class of antimalarial drugs.
Researchers have identified two key proteins that act as genetic 'architects', creating the blueprint needed by embryos during the earliest stages of their development.
Australian researchers have discovered the protein MCL-1 is critical for keeping milk-producing cells alive and sustaining milk production in the breast. Without milk production, offspring cannot survive, making MCL-1 essential ...
Walter and Eliza Hall Institute researchers have defined for the first time how the size of the immune response is controlled, using mathematical models to predict how powerfully immune cells respond to infection and disease.
Walter and Eliza Hall Institute researchers have for the first time revealed how dying cells are hidden from the immune 'police' that patrol the body.
Melbourne researchers are homing in on a new target for malaria treatment, after developing a compound that blocks the action of a key 'gatekeeper' enzyme essential for malaria parasite survival.
Scientists at the Walter and Eliza Hall Institute and their collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients.
Scientists at the Walter and Eliza Hall Institute have for the first time visualised the molecular changes in a critical cell death protein that force cells to die.